Replimune Group Inc. 的批准依据,聚焦于客观缓解率与缓解持续时间这两个关键指标。然而,这并非终点——确证性试验的要求,如同悬在头顶的利剑,仍需后续完成。
Replimune Group Inc. 的批准依据,聚焦于客观缓解率与缓解持续时间这两个关键指标。然而,这并非终点——确证性试验的要求,如同悬在头顶的利剑,仍需后续完成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.